We are seeking to explore the true story of AI: where are we now, what do we need to overcome, and how should we integrate this technology within the genomics sphere?
Personalised medicine has been a goal of researchers and doctors for a long time. Now, researchers have developed what they call a personalised Therapeutic Intervention Fingerprint (pTIF), for patients with neurological disease.
Researchers have created an artificial intelligence system for predicting, not simply tracking, potential side effects from drug combinations.
Phenotyping trailblazers are proving an impressive success in the clinic as the continue to go from strength to strength.
Researchers at Caltech have developed an artificial neural network made out of DNA that can solve a classic machine learning problem: Correctly identifying handwritten numbers.
China’s government is prioritising world-class science and tech. An expert describes the Chinese research landscape – and questions its sustainability.
Researchers have developed a type of personalised machine learning that helps robots estimate the engagement and interest of each a child during autism therapy, using data that are unique to that child.
A team of researchers have invented a new cell identification and sorting system that combines a novel imaging technique with artificial intelligence, to identify and sort cells with unprecedented high-throughput speed.
Sometimes a new company catches the eye, and this week that company is nference, a Cambridge MA-based start-up developing AI technology to discover and develop drugs more effectively. AI is no longer new in this space, so why does nference grab our attention?
The U.K. Prime Minister, Theresa May has made her first appearance in a series on industrial strategy, whereby she has pledged millions of pounds of government funding to develop artificial intelligence to transform outcomes through early diagnosis of cancer and chronic disease.